Which is better, BIO or LLY?

On the Buffett-Fit framework, Eli Lilly and Company (LLY) currently grades higher than BIO — 72/100 (B grade) vs 43/100 (D). That said, "better" depends on which framework you trust — BIO wins on none; LLY wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy BIO or LLY?

This page is an educational comparison, not investment advice. Both BIO and LLY are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is BIO better than LLY for value investing?

On the Buffett-style value-investing framework, LLY currently grades higher — 72/100 vs 43/100, a 29-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between BIO and LLY on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). BIO currently scores 43/100 (D grade); LLY scores 72/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, BIO or LLY?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. BIO and LLY are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, BIO or LLY?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are BIO and LLY both Healthcare stocks?

Yes — both Bio-Rad Laboratories, Inc. (BIO) and Eli Lilly and Company (LLY) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this BIO vs LLY comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Bio-Rad Laboratories

Eli Lilly

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

BIO

Market cap

$7.78B

Sector

Healthcare

LLY

Eli Lilly

Market cap

$1T

Sector

Healthcare

Overall winner

Eli Lilly LLY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	BIO	LLY	Winner
Warren Buffett	43D	72B	LLY
Benjamin Graham	48D	86A	LLY
Philip Fisher	30F	86A	LLY
Peter Lynch	10F	74B	LLY
Joel Greenblatt	42D	78C	LLY
Charlie Munger	34F	85A	LLY
Terry Smith	26F	77C	LLY

Side-by-side metrics

Metric	BIO	LLY
Market cap	$7.78B	$1T
P/E (TTM)	39.5x	36.6x
EV/EBIT	28.0x	34.1x
ROIC (TTM)	1.95%	32.06%
Gross margin	51.87%	83.51%
Net margin	6.52%	34.98%
Revenue CAGR 5y	-3.04%	23.17%
EPS CAGR 5y	-33.51%	40.81%
Debt / Equity	0.2x	1.4x
Dividend yield	0.0%	0.62%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

BIO leads on

Debt / Equity0.2xvs 1.4x+86%
EV/EBIT28.0xvs 34.1x+18%

LLY leads on

EPS CAGR 5y40.81%vs -33.51%+182%
Revenue CAGR 5y23.17%vs -3.04%+113%
Dividend yield0.62%vs 0.0%+100%
Market cap$1Tvs $7.78B+99%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Bio-Rad Laboratories

Eli Lilly

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like BIO

More like LLY

Related on invest-like

Key terms in this analysis